| 51 |
17555881 | A proposed fairer method for conducting rofecoxib trials. | 2007 |
1 |
| 52 |
17612044 | Anti-inflammatory drugs in the 21st century. | 2007 |
1 |
| 53 |
17652824 | Anti-inflammatory and side effects of cyclooxygenase inhibitors. | 2007 May-Jun |
1 |
| 54 |
17661262 | [Cardiovascular toxicity of selective COX-2-inhibitors and classical NSAIDs]. | 2007 Jul |
2 |
| 55 |
17786211 | The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction. | 2007 Sep 5 |
1 |
| 56 |
17878525 | Molecular analysis of xenograft models of human cancer cachexia--possibilities for therapeutic intervention. | 2007 May-Jun |
1 |
| 57 |
17880512 | Modulation of hypericin photodynamic therapy by pretreatment with 12 various inhibitors of arachidonic acid metabolism in colon adenocarcinoma HT-29 cells. | 2007 Sep-Oct |
1 |
| 58 |
17906610 | Drug insight: cyclo-oxygenase-2 inhibitors--a critical appraisal. | 2007 Oct |
1 |
| 59 |
18473007 | Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice? | 2007 Oct |
1 |
| 60 |
19804301 | Rosiglitazone: a disappointing DREAM. | 2007 Sep |
1 |
| 61 |
16188370 | The cyclooxygenase-2 inhibitor rofecoxib (Vioxx) in the treatment of cervical dysplasia grade II-III A phase II trial. | 2006 Apr 1 |
1 |
| 62 |
16401468 | Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. | 2006 Jan |
1 |
| 63 |
16412030 | Chemoprevention of colorectal cancer with nonsteroidal anti-inflammatory drugs. | 2006 |
1 |
| 64 |
16519515 | Molecular dynamics simulations of arachidonic acid-derived pentadienyl radical intermediate complexes with COX-1 and COX-2: insights into oxygenation regio- and stereoselectivity. | 2006 Mar 14 |
2 |
| 65 |
16529558 | Cyclooxygenase inhibitory natural products: current status. | 2006 |
4 |
| 66 |
16544582 | Nasal and bronchial tolerability of Rofecoxib in patients with aspirin induced asthma. | 2006 Jan |
3 |
| 67 |
16599250 | Rofecoxib, as a safe alternative for acetyl salicylic acid/nonsteroidal anti-inflammatory drug-intolerant patients. | 2006 |
1 |
| 68 |
16827136 | COX-2 inhibitors celecoxib and rofecoxib prevent oxidative DNA fragmentation. | 2006 May-Jun |
1 |
| 69 |
16934053 | The effect of the withdrawal of rofecoxib on prescribing patterns of COX-2 inhibitors in Scotland. | 2006 Sep |
2 |
| 70 |
16939524 | Risk of hospitalization for angio-oedema among users of newer COX-2 selective inhibitors and other nonsteroidal anti-inflammatory drugs. | 2006 Oct |
1 |
| 71 |
16998619 | Ibuprofen as a pre-emptive analgesic is as effective as rofecoxib for mandibular third molar surgery. | 2006 Sep |
1 |
| 72 |
17024689 | The impact of NSAID or COX-2 inhibitor use on the initiation of antihypertensive therapy. | 2006 Dec |
1 |
| 73 |
17030482 | Structure-based pharmacophore of COX-2 selective inhibitors and identification of original lead compounds from 3D database searching method. | 2006 Dec |
1 |
| 74 |
17087947 | A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. | 2006 Dec |
1 |
| 75 |
17115981 | Prophylactic COX 2 inhibitor: an end to the Yom Kippur headache. | 2006 Nov-Dec |
1 |
| 76 |
17154669 | Use of nonsteroidal anti-inflammatory drugs in patients with aspirin hypersensitivity : safety of cyclo-oxygenase-2 inhibitors. | 2006 |
1 |
| 77 |
18690928 | The role of the New Zealand Intensive Medicines Monitoring Programme in identification of previously unrecognised signals of adverse drug reactions. | 2006 May |
2 |
| 78 |
15494548 | Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity. | 2005 Mar |
2 |
| 79 |
15572651 | The cyclooxygenase-2 inhibitor GW406381X [2-(4-ethoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-pyrazolo[1,5-b]pyridazine] is effective in animal models of neuropathic pain and central sensitization. | 2005 Mar |
1 |
| 80 |
15663617 | Intracranial hypertension induced by rofecoxib. | 2005 Jan |
1 |
| 81 |
15733024 | Do selective cyclo-oxygenase-2 inhibitors have a future? | 2005 |
1 |
| 82 |
15742005 | A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. | 2005 Jun |
1 |
| 83 |
15789535 | [Tubulointerstitial nephritis associated with treatment with selective Cox-2 inhibitors, celecoxib and rofecoxib]. | 2005 |
1 |
| 84 |
15834531 | [Extreme sinus bradycardia (30/min) with acute right heart failure under tizanidine (Sirdalud). Possible pharmacological interaction with rofecoxib (Vioxx)]. | 2005 Apr 15 |
1 |
| 85 |
15870389 | A novel celecoxib derivative potently induces apoptosis of human synovial fibroblasts. | 2005 Aug |
1 |
| 86 |
15899741 | Celecoxib-induced nephrotoxicity in a renal transplant recipient. | 2005 May |
1 |
| 87 |
15902994 | Selective COX-2 inhibition with different doses of rofecoxib does not impair endothelial function in patients with coronary artery disease. | 2005 Feb |
1 |
| 88 |
15911218 | AZD3582 increases heme oxygenase-1 expression and antioxidant activity in vascular endothelial and gastric mucosal cells. | 2005 Jun |
1 |
| 89 |
15934855 | The safety of rofecoxib. | 2005 May |
1 |
| 90 |
15974940 | Impact of COX-2 inhibitors in common clinical practice a gastroenterologist's perspective. | 2005 |
1 |
| 91 |
15974942 | COX inhibition and NSAID-induced gastric damage--roles in various pathogenic events. | 2005 |
1 |
| 92 |
15977092 | Preemptive oral rofecoxib plus postoperative intraarticular bupivacaine for pain relief after arthroscopic knee surgery. | 2005 Apr |
1 |
| 93 |
15981408 | Cox-2 inhibitors: still no decisive action. | 2005 Jun |
1 |
| 94 |
15998959 | Utilization of non-steroidal anti-inflammatory drugs in Quebec: adherence to the Canadian consensus on prescription guidelines. | 2005 Summer |
1 |
| 95 |
15999628 | [The medical reason for the prescription of COX-2 selective cyclo oxygenase inhibitor rofecoxib for the treatment of rheumatoid arthritis. A post-marketing surveillance study from Austria]. | 2005 May |
1 |
| 96 |
16024204 | The influence of anti-inflammatory drugs on the proliferation of fibroblast derived from nasal polyps. | 2005 Sep |
1 |
| 97 |
16035651 | The effects of rofecoxib on 24-h ambulatory blood pressure and heart rate monitoring in patients with hypertension and osteoarthritis. | 2005 |
1 |
| 98 |
16083531 | Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray? | 2005 Aug |
1 |
| 99 |
16088245 | Risk of retinal vein occlusions in patients treated with rofecoxib (vioxx). | 2005 Jul-Aug |
2 |
| 100 |
16091477 | Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism. | 2005 Oct |
1 |